ChrysCapital acquires Novartis India

ChrysCapital's Fund X has agreed to acquire a 14.23% stake in Novartis India Limited from Novartis AG. The transaction, amounting to INR 2.5 billion, aligns with ChrysCapital's ongoing investment strategy. The deal was announced on February 19, 2026, and remains pending, subject to regulatory approvals.

ChrysCapital Advisors LLP, alongside Two Infinity Partners, manages the acquiring fund. Novartis AG, headquartered in Basel, Switzerland, is divesting this minority stake as part of its broader strategic realignment. The specific details of the stake purchase and how it fits into Novartis AG's current global strategy have not been disclosed publicly.

The acquisition underlines ChrysCapital’s intent to solidify and possibly expand its footprint in the Indian pharmaceutical sector. By acquiring a stake in Novartis India, ChrysCapital is positioning itself to capitalize on the growth potential in the region, driven by increasing healthcare demands. The transaction could also create new opportunities for collaboration, potentially fostering innovation within the industry.

In a broader market context, this acquisition comes amid heightened interest from private equity in the pharmaceutical sector across emerging markets. Competitors and peers may view this as a signal of confidence in India's economic prospects and the potential for growth in its healthcare sector. This move reflects the competitive dynamics, where asset allocation is increasingly focused on high-growth potential markets.

Future scrutiny will focus on regulatory clearances necessary for the acquisition's completion. Market participants will also be keenly observing whether ChrysCapital intends to increase its shareholding further or leverage this entry into large-scale strategic arrangements within India's pharmaceutical landscape. As the deal advances, any significant changes in sector strategy or shifts in market behavior will be closely monitored.